The chief executive of St. Jude Medical Inc (STJ.N) said a slate of new products, including new ways of treating irregular heartbeats called atrial fibrillation, should ensure continued strong profit growth for the medical device maker. Daniel Starks, speaking on Friday at St. Jude's annual investor meeting in New York, said his company's recent financial performance has left most rivals "in the dust" and that Wall Street is not yet fully aware of the sales potential of varied types of experimental products it is now introducing or will soon launch. The company said the new products will help deliver "sustained double-digit" company sales growth, and that it has adequate cash flow to continue to repurchase shares and make new acquisitions.
Source
